Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Mercado Continuo Espanol  >  Grifols SA       ES0171996012

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2015 3 871 M
EBIT 2015 970 M
Net income 2015 566 M
Debt 2015 3 533 M
Yield 2015 1,79%
Sales 2016 4 102 M
EBIT 2016 1 065 M
Net income 2016 621 M
Debt 2016 3 198 M
Yield 2016 1,99%
P/E ratio 2015 20,09
P/E ratio 2016 19,65
EV / Sales 2015 3,82x
EV / Sales 2016 3,52x
Capitalization 11 250 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through four segments: Bioessence,... 
Sector
Pharmaceuticals
Calendar
02/29Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
02/04 GRIFOLS : Enters into Agreement with MassBiologics
01/27 HOLOGIC : Announces Financial Results for First Quarter of Fiscal 2016
01/26 GRIFOLS : invests in the project led by AlbaJuna Therapeutics, a spin-off from I..
01/26 GRIFOLS : invests in the project led by AlbaJuna Therapeutics, a spin-off from I..
01/26 GRIFOLS : invests in the project led by AlbaJuna Therapeutics, a spin-off from I..
01/11 GRIFOLS : Obtains Exclusive Rights to Market and Distribute MassBiologics' Tetan..
01/04 GRIFOLS SA : Split: 2 for 1
01/04 GRIFOLS CL. A : Split: 2 for 1
More news
Sector news : Biopharmaceuticals
09:05p ABBOTT LABORATORIES : Labs launches snack bars
06:58p PFIZER : Commends The FDA Advisory Committee’s Vote To Approve Proposed Bi..
06:10p TAKEDA PHARMACEUTICAL : and Zinfandel Pharmaceuticals Complete Enrollment in TOM..
More sector news : Biopharmaceuticals
News from SeekingAlpha
01/04 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Comments 
Advertisement
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | ES0171996012 | 4-Traders
Full-screen chart
Technical analysis trends GRIFOLS SA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions